Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

180 Life Sciences 

Citius Pharmaceuticals

Ocugen, Inc.

Savara

Timber Pharmaceuticals

Zosano Pharma

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

7 Reddit Penny Stocks to Buy for a Biotech Boom

Merger of Napo EU and Dragon SPAC targeted for mid-2021 Jaguar kicks off educational awareness contest in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV SAN FRANCISCO, CA / ACCESSWIRE /  April 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced the upsizing by $15.3 million of the at-the-market ("ATM") financing program the Company established on October 5, 2020 with Ladenburg Thalmann & Co. Inc. ("Ladenburg") for potential future financing needs. On April 9, 2021, the Company filed a registration statement and prospectus supplement in connection with its previously disclosed At The Market Offering Agreement with Ladenburg, as agent, to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time through Ladenburg, shares (the "ATM Shares") of the Company's common stock.

Jaguar Health Announces Upsizing of At-the-Market (ATM) Financing Program by $15.3 Million with Ladenburg Thalmann & Co. Inc. for Potential Future Financing Needs

SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's collaborators has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held virtually from June 4-8, 2021. Two other CTD-related abstracts from Napo and its collaborators have also been accepted for online publication for the 2021 ASCO Annual Meeting.

Jaguar Health and Napo Pharmaceuticals Announce Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting

Stock purchase price under the agreement increases to $3.00 per share SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar has entered into an amendment (the "Amendment") to the March 24, 2020 equity purchase agreement (the "Equity Purchase Agreement") with Oasis Capital, LLC ("Oasis Capital"). As previously announced, Oasis is committed to purchasing up to an aggregate of $2.0 million of Jaguar common stock over the 36-month term of the Equity Purchase Agreement.

Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC

SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has promoted Carol Lizak, an accomplished financial executive, to the expanded role of chief financial officer. "We are thrilled to have Carol take on this important and expanded role as part of Jaguar's management team.

Jaguar Health Promotes Carol Lizak to Chief Financial Officer

It's easy to dismiss JAGX stock as just another beneficiary of the equity bull market. However, Jaguar Health has made significant strides during the last year.

Jaguar Health Has Enough Short-Term Catalysts To Make It Interesting

Jaguar Health (JAGX) stock is heading higher on Thursday following the release of the biopharma company's earnings for the full year of 2020. The post JAGX Stock: 15 Things Giving Jaguar Health Shares a Jolt Today appeared first on InvestorPlace.

JAGX Stock: 15 Things Giving Jaguar Health Shares a Jolt Today

The stock price of Jaguar Health, Inc. (NASDAQ:JAGX) increased by over 10% pre-market. This is why it happened.

JAGX Stock Price Increased Over 10% Pre-Market: Why It Happened

Mytesi® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2020. 2020 Company Financial Results: Mytesi® Net Product Revenue: 2020 Mytesi net sales were approximately $9.3 million, and Mytesi gross (non-GAAP) sales were approximately $20.4 million, an increase of 64% and 148%, respectively, year over year.

Jaguar Health Reports 2020 Financial Results and Business Updates

Update regarding March 15, 2021 meeting with European regulatory authority regarding potential Covid-related indication for crofelemer SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company supports the selection of the investment bank and nominated advisor ("NOMAD") made by the lead sponsor of the planned Dragon special purpose acquisition company (the "Dragon SPAC"). The Dragon SPAC anticipates listing on AIM Italia and merging with its named target, Napo EU S.p.A.

Jaguar Health Announces Selection of Investment Bank and Nominated Advisor for Proposed Merger of the Dragon SPAC and Napo EU, Jaguar's Italian Subsidiary

New educational contest to begin in April in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV SAN FRANCISCO, CA / ACCESSWIRE / March 22, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Maribel P.L., a nurse from New York, is the winner of the Company's International Day of Forests educational awareness contest.

Jaguar Health Announces Winner of International Day of Forests Contest

Napo EU will serve as the foundation of the Company's efforts to address the growing burden - particularly in Europe - of the inflammatory diarrhea associated with long-hauler syndrome in the post COVID-19 patient population In honor of International Day of Forests, Company is conducting a survey contest to raffle off a signed print of an original painting of a Jaguar by Anthony J. Conte - link to entry form appears below SAN FRANCISCO, CA / ACCESSWIRE / March 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Napo EU S.p.A.

Jaguar Health Announces Incorporation of Napo EU Subsidiary in Italy

AIM ImmunoTech Inc

Asensus Surgical

Celsion

iBio

Ovid Therapeutics

Rigel Pharmaceuticals

VBI Vaccines

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

8 Biotech Penny Stocks for Investors to Watch

No royalty payments due for 36 months Company has started to identify key opinion leader physicians in the US as well as Europe focused on addressing the symptoms - including gastrointestinal distress - that afflict a significant proportion of COVID-19 survivors for an extended period after recovery SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has signed the definitive agreement (the "Agreement") related to the previously announced term sheet for a third non-dilutive royalty financing transaction, pursuant to which Jaguar is selling to the lender for an aggregate purchase price of $5 million (the "Royalty Purchase Price") a royalty interest in future potential crofelemer (Mytesi®) sales for the proposed COVID-related indication in long-hauler patients (as defined below), for which the Company is currently exploring the pathway of conditional marketing authorization in the European Union. The COVID-related indication is the initial indication to be pursued by Napo EU, the exclusive target of the planned Dragon special purpose acquisition company (the "Dragon SPAC"), which is anticipated to be listed on AIM Italia.

Jaguar Health Signs Definitive Agreement for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream

Continuing Friday's rally, Jaguar Health Inc (NASDAQ: JAGX) stock has surged on Monday as the investors react to the news of its third royalty financing agreement announced on Friday. The company entered a binding term sheet for $5 million a royalty interest in future potential crofelemer (Mytesi) sales for the proposed COVID-related indication in long-hauler patients.

Why Are Jaguar Health Shares Surging Today?

The stock price of Jaguar Health Inc (NASDAQ: JAGX) has increased by over 55% during intraday trading. This is why it happened.

JAGX Stock Price Increased Over 55% Intraday: Why It Happened

JAGX stock is on the move today after Jaguar Health announced a plan to secure $5 million of funding. Here's what to know now.

JAGX Stock: Why Popular Jaguar Health Is Climbing Today

AMC Entertainment

Express

GameStop

Koss

SNDL Inc.

Zomedica

These seven meme stocks have been caught up in the short squeeze, and have grown immensely despite showing little promise from their fundamentals. The post 7 Meme Stocks That Have Retail Traders ‘Stonk-ing' Up appeared first on InvestorPlace.

7 Meme Stocks That Have Retail Traders ‘Stonk-ing' Up

JAGX stock has risen dramatically on positive sentiment about the potential for an expanded market for the company's core Mytesi drug. The post Is the Parabolic Rise of JAGX Stock Too Good to Be True?

Is the Parabolic Rise of JAGX Stock Too Good to Be True?

No royalty payments due for 36 months Planned COVID-related indication in long-hauler patients is the lead focus for crofelemer at Napo EU, the exclusive target of the planned Dragon SPAC, which is pursuing listing on AIM Italia Company expects to provide additional updates regarding Napo EU next week SAN FRANCISCO, CA / ACCESSWIRE / March 5, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has entered a binding agreement of terms (the "Term Sheet") for a third non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the lender for an aggregate purchase price of $5 million (the "Royalty Purchase Price") a royalty interest in future potential crofelemer (Mytesi®) sales for the proposed COVID-related indication in long-hauler patients (as defined below), for which the Company is currently exploring the pathway of conditional marketing authorization in the European Union. Jaguar intends to use the proceeds from the proposed transaction to support regulatory activities associated with the Company's development pipeline, including supporting the development program for crofelemer for the prophylaxis and/or symptomatic relief of inflammatory diarrhea, initially to be studied in a long-hauler COVID-19 recovery patient population (the "COVID-related indication").

Jaguar Health Enters Binding Term Sheet for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream

Jaguar Health is doing the right thing while JAGX stock is on the skids. It is falling into support, so there could be relief coming.

Jaguar Health Is on a Noble Mission But the Stock Needs a Nudge

Jaguar Health did not have a good February. Down 25% through Feb. 25, it might be time to give up on JAGX stock despite SPAC spinoff.

Is Jaguar Health Ready to Bounce Back From a Lousy February?

Avid Bioservices

CytoDyn Inc.

Fulgent Genetics

Humanigen

PureTech Health PLC

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

7 Biotech Stocks Focused on Chronic Covid Treatment

JAGX stock needs to prove the effectiveness of its drug candidates before investors can consider jumping on its bandwagon. The post Jaguar Health Has Promise, But It's Not a Good Investment Yet appeared first on InvestorPlace.

Jaguar Health Has Promise, But It's Not a Good Investment Yet

Jaguar Health Inc (NASDAQ: JAGX) has signed a Memorandum of Understanding (MoU) with the lead sponsor of the planned Dragon special purpose acquisition company, pursuing a listing on AIM Italia. Per the MOU, Napo EU, the company's anticipated subsidiary in Italy, will be the named target of the Dragon SPAC and has granted latter exclusivity to list on AIM Italia and negotiate and finalize documentation for the contemplated merger transaction.

News for Jaguar Health Stock (JAGX)